DBV Files Biologics License Application for Young Kids

DBV Technologies submitted its application for children aged 4 to 7 years, as its contract manufacturer faces an FDA Warning Letter.

Updated on Nov. 18, 2026 in Allergies

Bold flat-color editorial illustration of matte steel process vessels and piping in a sterile corridor, evoking pharmaceutical manufacturing under regulatory review.
DBV Technologies has filed a Biologics License Application for its skin-patch therapy for children aged 4 to 7, as its contract manufacturer faces an FDA Warning Letter. AI Illustration. Upload story photo >

DBV Technologies announced on its third-quarter 2026 earnings call on October 28, 2026, that it has submitted a Biologics License Application for children aged 4 to 7 years. The company's contract manufacturer, Fareva Amboise, received an FDA Warning Letter regarding sitewide quality management issues.

Why it matters

The filing advances DBV's proprietary skin-patch therapy for pediatric food allergies toward a possible U.S. decision. The manufacturer's regulatory issues add a dependency that management says it is working to resolve before a pre-approval inspection.

DBV ended the quarter with $165.7 million in cash and cash equivalents, and it links its spending to regulatory progress. Management has not said when FDA will act on the application or when the manufacturer's quality issues will be resolved.

The players

DBV Technologies

DBV Technologies is a biopharmaceutical company developing a proprietary skin-patch therapy for pediatric food allergies.

Fareva Amboise

Fareva Amboise is a contract manufacturer whose facility in Amboise, France, received an FDA Warning Letter regarding sitewide quality management issues.

The details

DBV sequenced its filings rather than submitting two complex applications at once, a choice management says helps avoid review bottlenecks at the FDA. Its contract manufacturer, Fareva Amboise, received an FDA Warning Letter over sitewide quality management, and internal quality teams are being aligned to complete remediation before the pre-approval inspection.

Timeline

  1. October 28, 2026: DBV announces the BLA submission on its third-quarter 2026 earnings call.

  2. Third quarter 2027: Projected end of cash runway under the company's milestone-based spending plan.

Health Landscape

The filing extends DBV's epicutaneous skin-patch approach, which delivers allergen through the skin rather than by mouth, toward a U.S. regulatory decision for children aged 4 to 7. It moves a patch-based alternative to oral immunotherapy closer to clinical use, though the manufacturer's FDA issues could affect timing.

If approved, the patch would offer families of young children with food allergies a skin-based option instead of oral immunotherapy. Any approval depends on FDA review and on the manufacturer resolving its quality issues before inspection.

The takeaway

Regulatory timing and manufacturing quality can shape when a new allergy therapy reaches patients as much as the clinical data does. Families tracking pediatric food allergy treatments should watch for FDA decisions on this filing.

Further reading

For background on the conditions this therapy targets, see Allergies.

Source note: This article includes information reported by The Motley Fool.